This phase 2 study of Jaktinib Dihydrochloride Monohydrate, an oral inhibitor of JAK1 、JAK2 and JAK3, is to assess efficacy and safety in patients with idiopathic pulmonary fibrosis.The study is a randomised,multicentre,double-blind,placebo-controlled,study.
Jaktinib Dihydrochloride Monohydrate for idiopathic pulmonary fibrosis